| Baseline | Day 1 | Day 2 | Day 4 | ||||
---|---|---|---|---|---|---|---|---|
 | Placebo N = 25 | Heparin N = 25 | Placebo N = 24 | Heparin N = 24 | Placebo N = 22 | Heparin N = 20 | Placebo N = 18 | Heparin N = 14 |
TAT, μg/L | 13.9 (6.2-37.9) | 8.7 (3.5-30.0) | 7.8 (4.9-20.7) | 8.1 (3.5-17.3) | 9.3 (3.9-15.7) | 7.3 (3.1-20.3) | 7.9 (4.3-11.0) | 7.2 (2.6-18.4) |
D-dimer, mg/L | 3.1 ± 6.3 | 2.4 ± 7.5 | 5.4 ± 11.3 | 2.8 ± 7.8 | 1.3 ± 2.0 | 0.67 ± 1.1 | 0.67 ± 1.1 | 0.52 ± 0.54 |
IL-6, pg/mL | 235 (44-1,699) | 187 (34-961) | 173 (71-547) | 182 (58-589) | 132 (36-497) | 105 (27-478) | 90 (34-313) | 60 (23-227) |
IL-8, pg/mL | 546 (219-1,383) | 559 (198-11,949) | 667 (255-2,633) | 1,396 (333-6,009) | 874 (381-1,901) | 1328 (369-2,895) | 691 (234-1,307) | 1,035 (246-1,812) |
TNFα, pg/mL | 11.8 ± 19.5 | 9.3 ± 12.7 | 7.3 ± 10.2 | 4.9 ± 7.3 | 5.9 ± 8.9 | 6.8 ± 13.3 | 7.9 ± 9.9 | 6.4 ± 7.9 |
SP-D, ng/mL | 162.6 (44.7-602.3) | 309.7 (51.7-805.9) | 305.1 (65.3-662.1) | 210.5 (36.0-901.5) | 153.8 (82.7-823.2) | 119.2 (78.4-368.1) | 136.1 (85.5-309.4) | 176.6 (43.8-399.6) |
CC-16, ng/mL | 180.0 ± 148.6 | 207.2 ± 137.8 | 176.8 ± 155.7 | 172.4 ± 123.7 | 225.5 ± 148.6 | 186.5 ± 150.0 | 229.8 ± 142.6 | 207.4 ± 237.9 |
RAGE, pg/mL | 2,015 ± 3,607 | 3,170 ± 5,428 | 3,717 ± 11,072 | 3,320 ± 6,472 | 1,564 ± 3,273 | 1,975 ± 3,633 | 563 ± 1,369 | 936 ± 1,737 |